BACKGROUND: Homeostasis of circulating T cells is regulated in complex ways that have not yet been well defined. The balance between type 1 and type 2 T-cell subsets in cancer patients is thought to modulate antitumor immunity. Meanwhile, CD4+CD25+ regulatory T cells (Treg), which are potent inhibitors of antitumor immune responses, also play an invaluable role in maintaining immune homeostasis. METHODS: Peripheral blood was obtained from 42 patients with squamous cell carcinoma of the head and neck (SCCHN) and 24 healthy age-selected donors. The percentages of T-cell subsets and their cytokine profiles expressed in response to ex vivo stimulation were studied by multicolor flow cytometry. RESULTS: Although patients with SCCHN had a lower percentage (p < .05) of circulating CD4+ T cells than healthy donors, CD4+CD25+ regulatory T cells (Treg) were increased in the patients (p < .01). A significant increase in Th1 and Th2 CD4+ T cells was observed in the patients after ex vivo stimulation with phorbol 12-myristate 13-acetate /ionomycin. The percent of Treg inversely correlated with that of total CD8+ T cells (p < .05), CD8+IFN-gamma+ (Tc1) cells (p < .05), and CD8+IL-4+ (Tc2) cells (p < .01). There was a highly significant correlation between Tc1 and Tc2 CD8+ T cells (p < .0001) in SCCHN patients but not in controls. CONCLUSIONS: Treg are increased in proportion in the circulation of patients with SCCHN. These cells appear to downregulate cytokine expression in both Tc1 and Tc2 subsets of CD8+ effector T cells, which may be responsible for antitumor responses.
BACKGROUND: Homeostasis of circulating T cells is regulated in complex ways that have not yet been well defined. The balance between type 1 and type 2 T-cell subsets in cancerpatients is thought to modulate antitumor immunity. Meanwhile, CD4+CD25+ regulatory T cells (Treg), which are potent inhibitors of antitumor immune responses, also play an invaluable role in maintaining immune homeostasis. METHODS: Peripheral blood was obtained from 42 patients with squamous cell carcinoma of the head and neck (SCCHN) and 24 healthy age-selected donors. The percentages of T-cell subsets and their cytokine profiles expressed in response to ex vivo stimulation were studied by multicolor flow cytometry. RESULTS: Although patients with SCCHN had a lower percentage (p < .05) of circulating CD4+ T cells than healthy donors, CD4+CD25+ regulatory T cells (Treg) were increased in the patients (p < .01). A significant increase in Th1 and Th2 CD4+ T cells was observed in the patients after ex vivo stimulation with phorbol 12-myristate 13-acetate /ionomycin. The percent of Treg inversely correlated with that of total CD8+ T cells (p < .05), CD8+IFN-gamma+ (Tc1) cells (p < .05), and CD8+IL-4+ (Tc2) cells (p < .01). There was a highly significant correlation between Tc1 and Tc2CD8+ T cells (p < .0001) in SCCHN patients but not in controls. CONCLUSIONS: Treg are increased in proportion in the circulation of patients with SCCHN. These cells appear to downregulate cytokine expression in both Tc1 and Tc2 subsets of CD8+ effector T cells, which may be responsible for antitumor responses.
Authors: S S Hampras; M Tommasino; Y Zhao; J L Messina; A R Giuliano; N A Fenske; B Cherpelis; R S Hesterberg; A A Akuffo; R P Amorrortu; J Balliu; L Vijayan; T Gheit; P K Epling-Burnette; D E Rollison Journal: Br J Dermatol Date: 2019-02-10 Impact factor: 9.302
Authors: Derrick Wansom; Emily Light; Dafydd Thomas; Francis Worden; Mark Prince; Susan Urba; Douglas Chepeha; Bhavna Kumar; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Jeffrey Moyer; Carol Bradford; Nisha D'Silva; Thomas Carey; Jonathan McHugh; Gregory Wolf Journal: Laryngoscope Date: 2012-01 Impact factor: 3.325
Authors: Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531
Authors: Bülent Karagöz; Oğuz Bilgi; Mahmut Gümüs; Alev Akyol Erikçi; Ozkan Sayan; Orhan Türken; Emin Gökhan Kandemir; Ahmet Oztürk; Mustafa Yaylaci Journal: Med Oncol Date: 2009-01-16 Impact factor: 3.064